Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Authorizes Broad Use Of Tamiflu And Relenza To Deal With Swine Flu Outbreak

This article was originally published in The Pink Sheet Daily

Executive Summary

Emergency Use Authorizations for Roche and GSK products facilitate distribution to wider population, including alternate dosing or use by individuals outside approved labeling. FDA’s Sharfstein testifies before Congress April 30.

You may also be interested in...



H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products

H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products

Flu Vaccine Licensure Depends On Adjuvant; Fall Vaccination Campaign Likely

Efforts are under way to expedite H1N1 vaccine development for a potential voluntary vaccine campaign in the fall, but how registration of the vaccine is handled by FDA depends on whether or not an adjuvant is used

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel